Award
National Institute of Allergy and Infectious Diseases 5R01AI111205-10
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease
Recipient
ABVACC, INC.
Award Amount
$697,200.00
Ceiling
$697,200.00
Awarded
February 19, 2026
Identifier
5R01AI111205-10
Award for developing a multivalent toxoid vaccine to prevent recurrent Staphylococcus aureus infections, including immunological studies and clinical trials.
Description
The project focuses on developing a multivalent toxoid vaccine against Staphylococcus aureus SSTI. It includes immunological studies in patients and mouse models, aims to evaluate the efficacy of a vaccine in preventing recurrent infections, and is scheduled to enter Phase 1 clinical trial in 2022. The project involves extensive immunological and microbiological research and runs from August 1, 2014, to February 28, 2027.